Role of implantable cardioverter defibrillator therapy in the management of high-risk patients.
Cardiovascular mortality from ventricular tachycardia (VT) and ventricular fibrillation (VF) continues to be a major health problem. Several therapeutic approaches are now available to treat patients with known VT/VF. Among the various therapeutic options are antiarrhythmic drugs, catheter or surgical ablation of VT focus, and implantable cardioverter defibrillator (ICD). The overall 2-year cardiovascular mortality is significantly reduced by ICD therapy. The ICD is particularly useful in patients with 1) no inducible but clinical VT/VF, 2) drug refractory VT/VF, and 3) VT/VF in association with left ventricular ejection fraction of less than or equal to 30%. Significant improvements in ICD therapy have already been made; these improvements include tiered antitachycardia therapy, antibradycardia pacing, lower defibrillation threshold, and longer life of generator. Further improvements are expected, including nonthoracotomy approach to defibrillation, pectoral implant, and dual chamber sensing. It is likely that with all of the advances in ICD therapy its acceptance as a therapeutic option will increase.
Akhtar
M
M
Electrophysiology Laboratory, University of Wisconsin, Sinai Samaritan Medical Center, Milwaukee 53233.
Avitall
B
B
Jazayeri
M
M
Tchou
P
P
Troup
P
P
Sra
J
J
Axtell
K
K
D003365:Costs and Cost Analysis; D004554:Electric Countershock / Q000191:economics / Q000295:instrumentation / Q000379:methods; D004867:Equipment Design; D005544:Forecasting; D006801:Humans; D017060:Patient Satisfaction; D019736:Prostheses and Implants; D012307:Risk Factors; D013610:Tachycardia / Q000401:mortality / Q000628:therapy*; D013617:Tachycardia, Supraventricular / Q000628:therapy; D013908:Thoracotomy; D014693:Ventricular Fibrillation / Q000401:mortality / Q000628:therapy*